NRAS-Mutant Melanoma: Response to Chemotherapy

被引：1
|
作者：
Soon, Christopher W. M. [1 ]
Algazi, Alain P. [2 ]
Cha, Edward N. [2 ]
Webb, Emma M. [3 ]
Daud, Adil I. [2 ]
机构：
[1] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Div Hematol & Oncol, Dept Med, San Francisco, CA 94115 USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94115 USA
来源：
ARCHIVES OF DERMATOLOGY | 2011年 / 147卷 / 05期
关键词：
PHASE-III; DACARBAZINE;
D O I：
10.1001/archdermatol.2011.85
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：626 / 627
页数：3
相关论文
共 50 条
  • [21] Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma
    Rebecca, Vito W.
    Alicea, Gretchen M.
    Paraiso, Kim H. T.
    Lawrence, Harshani
    Gibney, Geoffrey T.
    Smalley, Keiran S. M.
    PIGMENT CELL & MELANOMA RESEARCH, 2014, 27 (06) : 1154 - 1158
  • [22] Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
    Bianca Dietsch
    Céline Weller
    Carsten Sticht
    Carolina de la Torre
    Martin Kramer
    Sergij Goerdt
    Cyrill Géraud
    Sebastian A. Wohlfeil
    BMC Cancer, 23
  • [23] Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
    Dietsch, Bianca
    Weller, Celine
    Sticht, Carsten
    de la Torre, Carolina
    Kramer, Martin
    Goerdt, Sergij
    Geraud, Cyrill
    Wohlfeil, Sebastian A.
    BMC CANCER, 2023, 23 (01)
  • [24] War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging
    Moschos, Stergios J.
    CLINICAL CANCER RESEARCH, 2022, 28 (14) : 2977 - 2979
  • [25] A novel mitochondrial inhibitor overcomes metabolic reprogramming and enhances the response of NRAS-mutant melanoma cells to MEK inhibition
    Rao, A.
    Smith, L.
    Parmenter, T.
    Schreuders, J.
    Butt, T.
    Tiganis, T.
    Culllinane, C.
    Hogg, P.
    McArthur, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S23 - S23
  • [26] Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma
    Akil, Hussein
    Quintana, Mercedes
    Raymond, Jeremy H.
    Billoux, Tommy
    Benboubker, Valentin
    Besse, Sophie
    Auzeloux, Philippe
    Delmas, Veronique
    Petit, Valerie
    Larue, Lionel
    D'Incan, Michel
    Degoul, Francoise
    Rouanet, Jacques
    CANCERS, 2021, 13 (06) : 1 - 20
  • [27] Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis
    Jaeger, Zachary J. J.
    Raval, Neel S. S.
    Maverakis, Natalia K. A.
    Chen, David Y. Y.
    Ansstas, George
    Hardi, Angela
    Cornelius, Lynn A. A.
    FRONTIERS IN MEDICINE, 2023, 10
  • [28] Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
    Schuler, Martin
    Zimmer, Lisa
    Kim, Kevin B.
    Sosman, Jeffrey A.
    Ascierto, Paolo A.
    Postow, Michael A.
    De Vos, Filip Y. F. L.
    van Herpen, Carla M. L.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Berking, Carola
    Reddy, Micaela B.
    Harney, Allison S.
    Berlin, Jordan D.
    Amaria, Rodabe N.
    CLINICAL CANCER RESEARCH, 2022, 28 (14) : 3002 - 3010
  • [29] A novel ERK inhibitor has potent activity in NRAS-mutant melanoma cancer models
    Kucia-Tran, J.
    Bevan, L.
    Ferraldeschi, R.
    Kidane, B.
    Lyons, J.
    Rich, S.
    Wallis, N.
    Munck, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E138 - E138
  • [30] Preclinical efficacy of MEK inhibition in Nras-mutant AML
    Burgess, Michael R.
    Hwang, Eugene
    Firestone, Ari J.
    Huang, Tannie
    Xu, Jin
    Zuber, Johannes
    Bohin, Natacha
    Wen, Tiffany
    Kogan, Scott C.
    Haigis, Kevin M.
    Sampath, Deepak
    Lowe, Scott
    Shannon, Kevin
    Li, Qing
    BLOOD, 2014, 124 (26) : 3947 - 3955
12345